Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rotork H1 order growth curbed by margin pressures

(Sharecast News) - Flow control specialist Rotork said on Tuesday that solid H1 order intake had been offset by softer margins and a dip in reported profits. Rotork said its Growth+ strategy continued to deliver across all divisions, with particularly strong momentum in water infrastructure and upstream oil markets. However, a shift in product mix and higher investment weighed on margins in its water and power segment.

Reported revenues were up 1.6% at £367.3m and order intake was 4.5% higher at £391.1m, but operating profits slipped 3.1% to £64.7m and operating margins contracted 90 basis points to 17.6% amid FX headwinds and transformation costs. Pre-tax profits were down 6.6% at £65.1m.

On an adjusted basis, operating profits were 5.7% higher, while operating margins expanded by 140 basis points to 22.0%, supported by efficiencies and a favourable sales mix in its oil and gas unit, where margins improved notably.

Rotork also flagged a healthy book-to-bill ratio and reiterated its FY guidance, citing visibility in its order book and pipeline.

Chief executive Kiet Huynh said: "We're pleased to see good first-half order growth across all divisions, underpinned by our Growth+ strategy. There was a particularly strong order performance in water and power driven by the Target Segment focus on markets such as water infrastructure and treatment.

"Sales momentum accelerated during the period and we are confident of further growth in the second half, supported by order-book visibility and our project pipeline."

As of 0915 BST, Rotork shares were up 1.39% at 321.20p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.